Carbon Nanomaterials: Efficacy and Safety for Nanomedicine

Takuya Yamashita^{1

2}, Kohei Yamashita^{3

4}, Hiromi Nabeshi^{5

6}, Tomoaki Yoshikawa^{7

8}, Yasuo Yoshioka^{9

10

11}, Shin-Ichi Tsunoda^{12

13

14}, Yasuo Tsutsumi^{15

16

17}

Affiliations

¹ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. t-yamashita@nibio.go.jp.
² Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. t-yamashita@nibio.go.jp.
³ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yamasita@phs.osaka-u.ac.jp.
⁴ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. yamasita@phs.osaka-u.ac.jp.
⁵ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. nabeshi@phs.osaka-u.ac.jp.
⁶ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. nabeshi@phs.osaka-u.ac.jp.
⁷ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tomoaki@phs.osaka-u.ac.jp.
⁸ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. tomoaki@phs.osaka-u.ac.jp.
⁹ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yasuo@phs.osaka-u.ac.jp.
¹⁰ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. yasuo@phs.osaka-u.ac.jp.
¹¹ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yasuo@phs.osaka-u.ac.jp.
¹² Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. tsunoda@nibio.go.jp.
¹³ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tsunoda@nibio.go.jp.
¹⁴ Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tsunoda@nibio.go.jp.
¹⁵ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. ytsutsumi@phs.osaka-u.ac.jp.
¹⁶ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. ytsutsumi@phs.osaka-u.ac.jp.
¹⁷ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. ytsutsumi@phs.osaka-u.ac.jp.

PMID: 28817050
PMCID: PMC5448911
DOI: 10.3390/ma5020350

Review

Carbon Nanomaterials: Efficacy and Safety for Nanomedicine

Takuya Yamashita et al. Materials (Basel). 2012.

. 2012 Feb 21;5(2):350-363.

doi: 10.3390/ma5020350.

Authors

Takuya Yamashita^{1

2}, Kohei Yamashita^{3

4}, Hiromi Nabeshi^{5

6}, Tomoaki Yoshikawa^{7

8}, Yasuo Yoshioka^{9

10

11}, Shin-Ichi Tsunoda^{12

13

14}, Yasuo Tsutsumi^{15

16

17}

Affiliations

¹ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. t-yamashita@nibio.go.jp.
² Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. t-yamashita@nibio.go.jp.
³ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yamasita@phs.osaka-u.ac.jp.
⁴ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. yamasita@phs.osaka-u.ac.jp.
⁵ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. nabeshi@phs.osaka-u.ac.jp.
⁶ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. nabeshi@phs.osaka-u.ac.jp.
⁷ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tomoaki@phs.osaka-u.ac.jp.
⁸ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. tomoaki@phs.osaka-u.ac.jp.
⁹ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yasuo@phs.osaka-u.ac.jp.
¹⁰ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. yasuo@phs.osaka-u.ac.jp.
¹¹ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. yasuo@phs.osaka-u.ac.jp.
¹² Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. tsunoda@nibio.go.jp.
¹³ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tsunoda@nibio.go.jp.
¹⁴ Laboratory of Biomedical Innovation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. tsunoda@nibio.go.jp.
¹⁵ Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. ytsutsumi@phs.osaka-u.ac.jp.
¹⁶ Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan. ytsutsumi@phs.osaka-u.ac.jp.
¹⁷ The Center for Advanced Medical Engineering and Informatics, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. ytsutsumi@phs.osaka-u.ac.jp.

PMID: 28817050
PMCID: PMC5448911
DOI: 10.3390/ma5020350

Abstract

Carbon nanomaterials, including fullerenes, carbon nanohorns, and carbon nanotubes, are increasingly being used in various fields owing to these materials' unique, size-dependent functions and physicochemical properties. Recently, because of their high variability and stability, carbon nanomaterials have been explored as a novel tool for the delivery of therapeutic molecules including peptide and nucleic acid cancer drugs. However, insufficient information is available regarding the safety of carbon nanomaterials for human health, even though such information is vital for the development of safe and effective nanomedicine technologies. In this review, we discuss currently available information regarding the safety of carbon nanomaterials in nanomedicine applications, including information obtained from our own studies; and we discuss types of carbon nanomaterials that demonstrate particular promise for safe nanomedicine technologies.

Keywords: carbon nanohorns; carbon nanomaterials; carbon nanotubes; drug delivery; fullerenes; nano safety science; nanomedicine.

PubMed Disclaimer

References

1. Konstantatos G., Sargent E.H. Nanostructured materials for photon detection. Nat. Nanotechnol. 2010;5:391–400. doi: 10.1038/nnano.2010.78. - DOI - PubMed
1. Augustin M.A., Sanguansri P. Nanostructured materials in the food industry. Adv. Food Nutr. Res. 2009;58:183–213. - PubMed
1. Bowman D.M., van Calster G., Friedrichs S. Nanomaterials and regulation of cosmetics. Nat. Nanotechnol. 2010;5:92. doi: 10.1038/nnano.2010.12. - DOI - PubMed
1. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010;9:615–627. doi: 10.1038/nrd2591. - DOI - PubMed
1. Stern S.T., McNeil S.E. Nanotechnology safety concerns revisited. Toxicol. Sci. 2008;101:4–21. doi: 10.1093/toxsci/kfm169. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Carbon Nanomaterials: Efficacy and Safety for Nanomedicine

Affiliations

Carbon Nanomaterials: Efficacy and Safety for Nanomedicine

Authors

Affiliations

Abstract

References

Publication types

LinkOut - more resources

Full Text Sources